CD19 and neoplasm: In order to obtain preliminary evidence of the clinical suitability of emapalumab to manage CAR-T cell toxicities, we first evaluated whether neutralization of the IFNγ axis affects the cytotoxic activity CAR-T cells against CD19+ tumor cells.